Diabetes Division, University of Massachusetts, Worcester, MA 01605, USA.
Exp Biol Med (Maywood). 2010 Nov;235(11):1328-37. doi: 10.1258/ebm.2010.010150.
Proteomic profiling of serum is a powerful technique to identify differentially expressed proteins that can serve as biomarkers predictive of disease onset. In this study, we utilized two-dimensional (2D) gel analysis followed by matrix-assisted-laser desorption/ionization time-of-flight mass spectrometry analysis to identify putative serum biomarkers for autoimmune type 1 diabetes (T1D) in biobreeding diabetes resistant (BBDR) rats induced to express the disease. Treatment with toll-like receptor 3 ligand, polyinosinic:polycytidilic acid (pIC), plus infection with Kilham rat virus (KRV), a rat parvovirus, results in nearly 100% of young BBDR rats becoming diabetic within 11-21 d. Sera collected from prediabetic rats at early time points following treatment with pIC + KRV were analyzed by 2D gel electrophoresis and compared with sera from control rats treated with phosphate-buffered saline, pIC alone or pIC + H1, a non-diabetogenic parvovirus. None of the latter three control treatments precipitates T1D. 2D gel analysis revealed that haptoglobin, an acute phase and hemoglobin scavenger protein, was differentially expressed in the sera of rats treated with pIC + KRV relative to control groups. These results were confirmed by Western blot and enzyme-linked immunosorbent assay studies, which further validated haptoglobin levels as being differentially increased in the sera of pIC + KRV-treated rats relative to controls during the first week following infection. Early elevations in serum haptoglobin were also observed in LEW1.WR1 rats that became diabetic following infection with rat cytomegalovirus. The identification and validation of haptoglobin as a putative serum biomarker for autoimmune T1D in rats now affords us the opportunity to test the validity of this protein as a biomarker for human T1D, particularly in those situations where viral infection is believed to precede the onset of disease.
血清蛋白质组学分析是一种强大的技术,可用于鉴定差异表达的蛋白质,这些蛋白质可作为疾病发作的预测生物标志物。在这项研究中,我们利用二维(2D)凝胶分析,然后进行基质辅助激光解吸/电离飞行时间质谱分析,以鉴定在诱导表达疾病的生物繁殖糖尿病抵抗(BBDR)大鼠中用于自身免疫 1 型糖尿病(T1D)的潜在血清生物标志物。用 Toll 样受体 3 配体聚肌苷酸:聚胞苷酸(pIC)处理,并用鼠细小病毒(KRV)感染,会导致近 100%的年轻 BBDR 大鼠在 11-21 天内变为糖尿病。用 pIC + KRV 处理后的早期糖尿病大鼠的血清进行 2D 凝胶电泳分析,并与用磷酸盐缓冲盐水、单独 pIC 或非致糖尿病细小病毒 H1 处理的对照大鼠的血清进行比较。后三种对照处理均未引发 T1D。2D 凝胶分析显示,触珠蛋白是一种急性期和血红蛋白清除蛋白,在 pIC + KRV 处理大鼠的血清中与对照组相比差异表达。Western blot 和酶联免疫吸附试验研究进一步证实了这一点,进一步验证了触珠蛋白水平在感染后第一周内 pIC + KRV 处理大鼠的血清中差异增加。在感染大鼠巨细胞病毒后发生糖尿病的 LEW1.WR1 大鼠中也观察到血清触珠蛋白的早期升高。触珠蛋白作为大鼠自身免疫性 T1D 的潜在血清生物标志物的鉴定和验证,现在为我们提供了机会来测试该蛋白作为人类 T1D 生物标志物的有效性,特别是在认为病毒感染先于疾病发作的情况下。